This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche
by Zacks Equity Research
Alnylam (ALNY) collaborates with Roche to co-develop and co-commercialize RNAi-based therapeutic, zilebesiran, for the treatment of hypertension in patients with high cardiovascular risk.
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Add Alnylam (ALNY) Stock to Your Portfolio
by Zacks Equity Research
Alnylam's (ALNY) revenues continue to be driven by Amvuttra and Givlaari sales. Its existing collaboration agreement with Regeneron to develop RNAi-based candidates is progressing well.
The Zacks Analyst Blog Highlights Microsoft, Salesforce, United Parcel Service, UnitedHealth and Alnylam
by Zacks Equity Research
Microsoft, Salesforce, United Parcel Service, UnitedHealth and Alnylam are included in this Analyst Blog.
Top Research Reports for Microsoft, Salesforce & United Parcel Service
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Salesforce, Inc. (CRM) and United Parcel Service, Inc. (UPS).
BridgeBio (BBIO) Up as Heart Drug Meets Primary Goal in Study
by Zacks Equity Research
BridgeBio's (BBIO) shares surge on announcing positive data from a late-stage study evaluating acoramidis for patients with transthyretin amyloid cardiomyopathy.
Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.
Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date
by Zacks Equity Research
Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of 51.22% and 44.56%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alnylam (ALNY) Reports Positive Results From APOLLO-B Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.
Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?
by Zacks Equity Research
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Nuveen ESG Mid-Cap Growth ETF (NUMG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for NUMG
Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQJ
Alnylam (ALNY) Q4 Earnings Top, Product Sales Boost Revenues
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports better-than-expected fourth-quarter 2022 results. Total revenues of the company continue to be driven by the sales of Onpattro, Givlaari, Oxlumo and the newly approved Amvuttra.
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 21.13% and 9.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Alnylam Pharmaceuticals (ALNY) Ahead of Earnings?
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More
by Kinjel Shah
Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.
Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.
Geron (GERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors will focus on updates on Geron's (GERN) lead pipeline candidate when it reports its fourth-quarter earnings.